Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Zanon

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Sciences|January 12, 2008
Kinetics and mechanism of the hydrolytic degradation of indinavir: intramolecular catalysisMaria M Toteva, Roger Zanon, Drazen Ostovic
Journal of Pharmacological and Toxicological Methods|September 6, 2011
hERG potency estimates based upon dose solution analysis: What have we learned?Yusheng Qu, Paul Schnier, Roger Zanon, et al.
International Journal of Pharmaceutics|January 5, 2002
Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetryLesley Mackin, Roger Zanon, Jung Min Park, et al.
Rapid Communications in Mass Spectrometry : RCM|August 31, 2002
High-throughput logP measurement using parallel liquid chromatography/ultraviolet/mass spectrometry and sample-poolingYining Zhao, Janan Jona, David T Chow, et al.
Journal of Medicinal Chemistry|August 19, 2007
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitorsMichele H Potashman, James Bready, Angela Coxon, et al.
Journal of Medicinal Chemistry|March 8, 2008
Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitorsMatthew M Weiss, Jean-Christophe Harmange, Anthony J Polverino, et al.
Journal of Medicinal Chemistry|March 8, 2008
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluationJean-Christophe Harmange, Matthew M Weiss, Julie Germain, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Sciences|January 12, 2008
Kinetics and mechanism of the hydrolytic degradation of indinavir: intramolecular catalysisMaria M Toteva, Roger Zanon, Drazen Ostovic
Journal of Pharmacological and Toxicological Methods|September 6, 2011
hERG potency estimates based upon dose solution analysis: What have we learned?Yusheng Qu, Paul Schnier, Roger Zanon, et al.
International Journal of Pharmaceutics|January 5, 2002
Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetryLesley Mackin, Roger Zanon, Jung Min Park, et al.
Rapid Communications in Mass Spectrometry : RCM|August 31, 2002
High-throughput logP measurement using parallel liquid chromatography/ultraviolet/mass spectrometry and sample-poolingYining Zhao, Janan Jona, David T Chow, et al.
Journal of Medicinal Chemistry|August 19, 2007
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitorsMichele H Potashman, James Bready, Angela Coxon, et al.
Journal of Medicinal Chemistry|March 8, 2008
Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitorsMatthew M Weiss, Jean-Christophe Harmange, Anthony J Polverino, et al.
Journal of Medicinal Chemistry|March 8, 2008
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluationJean-Christophe Harmange, Matthew M Weiss, Julie Germain, et al.
Pageof 1